Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan

Chia-Hung Liu1,2†, Jiun-Ling Wang3†, Chia-Ping Su4†, Jen-Hsiang Chuang4, Chia-Hsuin Chang1,5* and Mei-Shu Lai1*

Abstract

Background: The Taiwan CDC provided free oseltamivir to all patients with influenza infections confirmed by rapid testing or who had clinical warning symptoms during the 2009 H1N1 influenza pandemic in Taiwan. However, oseltamivir utilization patterns, cost, and outcomes among oseltamivir-treated patients remained unclear.

Method: A population-level, observational cohort study was conducted using the Taiwan National Health Insurance Database from January to December 2009 to describe the use of oseltamivir.

Result: Prescription trend over weeks increased after a change in government policy and responded to the influenza virus activity. The overall prescription rate was 22.33 per 1000 persons, with the highest prescription rate of 116.5 for those aged 7–12 years, followed by 69.0 for those aged 13–18 years, while the lowest rate was 1.7 for those aged ≥65 years. As influenza virus activity increased, the number of prescriptions for those aged ≤18 years rose significantly, whereas no substantial change was observed for those aged ≥65 years. There were also regional variations in terms of oseltamivir utilization and influenza complication rates.

Conclusions: Oseltamivir was widely used in the 2009 H1N1 influenza pandemic in Taiwan, particularly in those aged 7–18 years. The number of prescriptions for oseltamivir increased with a change in government policy and with increasing cases of pandemic influenza. Further study is needed to examine whether there is an over- or under-use of anti-influenza drugs in different age groups or regions and to examine the current policy of public use of anti-influenza drugs to reduce influenza-associated morbidity and mortality.

Keywords: Oseltamivir, Influenza A virus, H1N1 subtype, Pandemic, Mortality

Background

The 2009 influenza A H1N1 pandemic was responsible for at least 18,000 deaths worldwide from March 2009 throughout August 2010 [1]. Oseltamivir, a neuraminidase inhibitor, is a widely-used anti-influenza agent to treat and prevent seasonal or pandemic influenza infections. The World Health Organization (WHO), the US Centers of Disease and Control (CDC), and the European Centre for Disease Prevention and Control recommend that governments stockpile and properly deliver anti-influenza agents to diminish the impact of pandemic influenza [2-4].

Despite the reports that oseltamivir may reduce influenza complications and hospitalizations, recent Cochrane reviews have found that oseltamivir can mitigate influenza-like illness (ILI) symptoms for 21 hours. However, the authors are unable to conclude the effect of oseltamivir on complications or transmission [5]. Based on the current evidence, criticisms have been raised of the public policy calling for mass oseltamivir prescription during the 2009 influenza A H1N1 pandemic [6].

In Taiwan, the first incidence of H1N1 infection was reported on May 20, 2009 and the first death occurred on July 30, 2009. To control viral transmission and reduce influenza-related morbidity and mortality, the Taiwan Centers of Disease Control (Taiwan CDC) has provided free antiviral agents (oseltamivir and zanamivir) since August 15, 2009 through the Bureau of National Health Insurance (BNHI) to all patients with influenza infections that were confirmed by rapid diagnostic
testing, or to those with influenza danger signs defined by WHO (including symptoms and signs suggesting oxygen impairment, cardiopulmonary insufficiency or central nervous system complications such as shortness of breath, tachypnea, altered mental status etc.) during the pandemic [3]. Receiving prescriptions for prophylaxis or stockpiling purposes was not allowed in the national health insurance program. However, under this policy, the utilization patterns, cost, and outcomes among oseltamivir-treated patients remained unclear. A clear understanding of oseltamivir utilization is important in terms of national medical resource allocation and policy making for disease control. Meanwhile, examining the utilization patterns of anti-influenza use can reveal whether clinicians have followed guidelines to protect high risk patient groups [7]. Therefore, we conducted a population-level, observational cohort study using the BNHI database from January to December 2009 to describe the frequency of oseltamivir use and outcomes of influenza patients in Taiwan.

Methods

Ethics
Taiwan Centers for Disease Control Research approved the protocol of this study and waived the need for written informed consent because this is a retrospective study based on data from administrative databases and involved only minimal risk.

Data source
In 1995, a compulsory, single-payer national health insurance (NHI) program was implemented in Taiwan. The NHI claims database includes complete records of outpatient visits, hospital admissions, prescriptions, disease states and vital status for 99% of the 23 million Taiwanese inhabitants. Influenza surveillance systems in Taiwan have been described in another paper [8]. We established longitudinal medical histories for each beneficiary by linking several computerized administrative and claims datasets, and National Death Registry data through the civil identification number unique to each beneficiary and the date of birth.

Study population
We identified patients who received oseltamivir prescriptions (anatomical therapeutic chemical [ATC] classification system code J05AH02) between January 1 and December 31, 2009. Data were further stratified according to prescribers’ characteristics (outpatient or inpatient use, region, and medical facility). We collected information of prescribed drug supply days, date of prescription, and total number of pills dispensed from the pharmacy prescription database. Data on patient characteristics, including age, gender, influenza diagnosis and related complications were obtained from inpatient and outpatient medical records.

Statistical analysis
The primary variables included the number of oseltamivir prescriptions and the rate of prescription per 1,000 persons in the overall population and for each age group, calculated with the use of 2009 census statistics in Taiwan. Prescription trend over weeks was reported in relation to influenza virus activity, as measured by positive H1N1 virus isolation rate from the Taiwan Centers for Disease Control Influenza Surveillance Virology Laboratory [8]. We also estimated the expenditures for oseltamivir and the proportion relative to the total outpatient expenditures related to influenza treatment.

To investigate the outcomes of oseltamivir-treated patients, we reported the hospitalization rate of patients who received oseltamivir treatment during outpatient visits and the proportion of patients hospitalized for influenza and related complications leading to poor outcomes, which was defined as respiratory failure or death. We also calculated the influenza complication rates in different age groups and regions based on the influenza surveillance data from Taiwan CDC.

Results

Utilization pattern
A total of 516,772 oseltamivir outpatient prescriptions were identified in 2009 in Taiwan. In contrast to only 489 prescriptions during January and July, the number of oseltamivir prescriptions increased dramatically after the oseltamivir reimbursement policy began in August, reaching its peak at week 48 and then gradually decreasing after the mass vaccination program began in November. The prescription trend was in general agreement with the H1N1 influenza virus positive isolation rate (Figure 1). Among the positive specimens in 2009 pandemic, there were 79.7% of influenza A (H1N1). Most oseltamivir use was for those aged 7–12 years (38.0%), whereas only 0.8% were prescribed for those aged ≥65 years (Table 1). The overall prescription rate was 22.33 per 1000 persons. Oseltamivir prescription trends varied for different age groups (Figure 2). Among all age groups, the highest prescription rate per 1000 persons was 116.5 for those aged 7–12 years, followed by 69.0 for those aged 13–18 years, while the lowest rate was 1.7 for those aged ≥65 years. The number of prescriptions for those aged ≤18 years rose significantly as influenza virus activity increased, whereas no substantial change was observed for those aged ≥65 years (Figure 2).

There was a substantial difference in oseltamivir prescription rates among different regions, with higher utilization in northern Taiwan than in southern Taiwan.
Overall, 57.7% of oseltamivir was prescribed by primary care doctors, followed by 20.5% by regional hospitals, and 10.9% for local hospitals and medical centers (Figure 3). Of note, oseltamivir was mostly prescribed by physicians in regional hospitals and medical centers in August, whereas prescriptions by primary care doctors substantially increased after September (Figure 3).

A total of 487,278 patients received oseltamivir treatment during outpatient visits and 1,535 patients received oseltamivir therapy while hospitalized from August and December 2009. As compared to patients receiving outpatient treatment, a greater proportion of hospitalized patients received oseltamivir treatment in the age groups 0–6 and ≥65 years (Table 2).

In 2009, expenditures for oseltamivir were 14.2 million US dollar (60.9 US dollar per 1,000 persons), accounting for 37.2% of the total expenditures related to outpatient visits for oseltamivir users.

### Outcomes of pandemic influenza A H1N1 and related complications

Among the oseltamivir-treated patients, 11.2% were diagnosed with a lower respiratory tract infection or pneumonia. Approximately 2.0% of patients received outpatient oseltamivir treatment requiring hospitalization, whereas 2.7% of hospitalized patients incurred respiratory failure or death. Among patients with influenza complications, 18.5% were aged <6 years, 69.4% were aged 6–65 years, and 12.2% were aged >65 years. Thirty-two percent (n=305) had underlying diseases. Most common underlying diseases reported were chronic lung disease (n=73), metabolic diseases (n=71), and cardiovascular diseases (n=54). The complication rates in different age groups and regions were also shown in Table 1. Region D and E,

| Age group | Number of prescriptions (%) (N = 516,283) | Prescription rate per 1000 persons | Influenza with complications per million persons |
|-----------|-----------------------------------------|-----------------------------------|-----------------------------------------------|
| 0-6       | 74,432 (14.4)                           | 51.4                              | 139.4                                         |
| 7-12      | 196,086 (38.0)                          | 116.5                             | 74.5                                          |
| 13-18     | 133,153 (25.8)                          | 69.0                              | 65.2                                          |
| 19-64     | 108,473 (21.0)                          | 7.0                               | 28.8                                          |
| ≥65       | 4,139 (0.8)                             | 1.7                               | 54.1                                          |

**Note:** Region A and B were in northern Taiwan. Region C was in central Taiwan. Region D and E were in southern Taiwan. Region F was in eastern Taiwan. Influenza with complications: influenza danger signs defined by WHO (including symptoms and signs suggesting oxygen impairment, cardiopulmonary insufficiency or central nervous system complications such as shortness of breath, tachypnea, altered mental status etc.).
which had the lowest oseltamivir prescription rates among all regions, did not have the highest complication nor mortality rates.

**Discussion**

Our study described the prescription pattern of oseltamivir in Taiwan during the 2009 influenza A H1N1 pandemic. Oseltamivir was widely used in Taiwan, with an overall prescription rate of 22.33 per 1000 persons. Despite the majority of outpatient use in school-aged children and adolescents, a substantially higher proportion of hospitalized patients receiving oseltamivir were those aged 0–6 years and 65 years or older. Our research did not show higher utilization of anti-influenza drugs associated with better outcome in population level during influenza pandemic. The benefits of anti-influenza therapy may vary among different age groups and geographical areas.

During the 2009 influenza A H1N1 pandemic, the US CDC and the WHO suggested prompt empirical neuraminidase inhibitor treatment for those with complicated illnesses regardless of previous health status and those at high risk for severe disease, such as children younger than 2 years old, adults aged 65 years and older, pregnant women, and those with chronic heart, lung, liver, kidney disorders, and weakened immune systems [4,9]. It was also recommended that treatment should start as early as possible even before definitive diagnostic test results become available [4,9]. In Taiwan, the government provided free anti-influenza treatment through the NHI system for influenza patients with either

![Figure 2](image1.png)

**Figure 2** Number of prescriptions across different age groups and rate of prescription per 1000 persons across different age groups.

![Figure 3](image2.png)

**Figure 3** Number of prescriptions from different medical facilities.
positive rapid diagnostic test results or with WHO defined danger signs [3]. And this free anti-influenza treatment policy did influence the usage pattern of anti-influenza drugs in Taiwan. The first peak of virus isolation of H1N1 in 35–36 week did not coincide with the usage of oseltamivir (data not shown). This may be explained by the Taiwan CDC providing free antiviral agents since August 15, 2009. Despite a concern that oseltamivir overuse could select resistant viruses, studies that examined countries with high levels of oseltamivir use did not find a significant percentage of oseltamivir resistant influenza virus emerging during H1N1 pandemic [10-12].

Our study showed that there was a substantial difference in oseltamivir use among age groups. The highest outpatient prescription proportion was observed for those aged 7–18 years old (64.3%), which was probably due to the high infectious rate in this age group [13-15]. However, according to current treatment guidelines, patients in this age group, who have uncomplicated illness and are not in a group known to be at higher risk of developing severe or complicated illness, may not need to be treated with neuraminidase inhibitors [2-4]. In contrast, individuals aged 65 years or older had a much lower outpatient prescription rate (0.8%) despite that they were more vulnerable to severe influenza-related complications, if they were to acquire an infection. From the ICD-9 diagnosis in outpatients department visit in Taiwan in 2009 pandemic, children and adolescents had about four-fold higher numbers of ILI visit comparison to those aged 65 years or older [7]. Children and adolescents had a six-fold higher incidence of seropositivity in comparison to those aged 65 years or older [13]. However, children and adolescents (aged 7–18) had a more than fifty-fold higher numbers of the anti-influenza prescriptions in comparison to those aged 65 years or older in this study. Similar findings were observed in the US; clinicians were less likely to provide anti-influenza agents to adults ≥65 years old with influenza, compared with younger adults [15]. The low oseltamivir utilization in elderly may be explained by atypical presentation in this age group and/or decreased sensitivity of rapid influenza diagnostic testing [16-18]. The use of rapid diagnostic tests would ensure oseltamivir were only prescribed to people with confirmed influenza, reducing inappropriate use [18]. However, reliance on typical influenza symptoms and rapid influenza diagnostic tests for clinical decision-making may lead to many influenza infections going untreated or causing a treatment delay [16]. A global pooled analysis showed the relative risk of death was highest in the age groups 50–64 and ≥65 years and the presence of chronic illness increased the likelihood of death [17]. In Taiwan, the elderly had a three-fold higher incidence of serious infection compared

| Table 2 Patients (%) receiving outpatient and inpatient oseltamivir treatment in 2009 |
|----------------------------------|----------------------------------|-----------------|
| Age group | Outpatient treatment (%) (N = 487,278) | Inpatient treatment (%) (N = 1,535) |
| 0-6 | 14.2 | 27.4 |
| 7-12 | 38.2 | 28.7 |
| 13-18 | 26.1 | 13.0 |
| 19-64 | 20.7 | 23.2 |
| ≥65 | 0.8 | 7.6 |
| Hospital levels | | |
| Primary care doctor | 57.7 | – |
| Local hospitals | 10.9 | 18.8 |
| Regional hospitals | 20.5 | 56.9 |
| Medical centers | 10.9 | 24.2 |

| Table 3 Oseltamivir prescription and mortality rate in country level during 2009 H1N1 pandemic from literature review |
|----------------------------------|-----------------|-----------------|-----------------|
| Country | Reference | Population (millions) | Study period | Oseltamivir per 100,000 population | Mortality rate per million (Ref 8) |
| Japan | Ref 9 | 128 | Aug 2009- Mar 2010 | 7625 | 1.55 |
| Norway | Ref 10 | 4.8 | Jan 2009- Dec 2009 | 5795.6 | 6.00 |
| US | Ref 11 | 307 | Apr 2009- Mar 2010 | 2420.5 | 7.04 |
| Taiwan | This article | 23.1 | Aug 2009-Dec 2009 | 2233.1 | 1.52 |
| UK | Ref 12 | 60.6 | July 2009- Feb 2010 | 1933.6 | 5.08 |
| Denmark | Ref 13 | 5.5 | Jan 2009- Dec 2009 | 959.6 | 4.53 |
| Germany | Ref 14 | 82.6 | Oct 2009- Dec 2009 | 405.3 | 1.6 |
| France | Ref 14 | 65 | Oct 2009- Dec 2009 | 122.6 | 3.02 |
| Spain | Ref 14 | 46.6 | Oct 2009- Dec 2009 | 40.9 | 5.82 |
| Italy | Ref 14 | 60 | Oct 2009- Dec 2009 | 29.3 | 3.13 |
to adolescents [13]. Further research is needed to evaluate whether there is an over- or under-utilization of anti-influenza agents among different age groups.

From a literature search from Pubmed, Medline and Google using keyword “oseltamivir”, “prescription” and country names, we identified 10 published articles and governmental reports on oseltamivir prescriptions in 2009 H1N1 pandemic (Table 3) (Figure 4) [19-24]. We collected the reported number of cumulative confirmed fatal 2009 pandemic influenza A (H1N1) from European Centre for Disease Prevention and Control [25]. A substantial difference in oseltamivir prescription rates was found among countries, with the highest rates in Japan and Norway. There was no significant relation between prescription rate and influenza-associated mortality at the population level by linear regression (slope of the regression line 0.03; p=0.933). This may be explained by different prescription policy and accessibility of anti-influenza drugs during H1N1 pandemic in different countries. Healthcare accessibility and the lack of a co-payment for anti-influenza therapy made Taiwan become one of the countries with the highest oseltamivir utilization in the world. We did not know whether high mortality even under high oseltamivir prescription was related to (1) most prescriptions were probably issued to those people with mild cases of influenza (2) delayed oseltamivir use; (3) poor prognosis in certain risk groups; (4) bacterial co-infections [26] or (5) different mortality definition. Some physical and social factors may impede access to early use of anti-influenza drugs with the potential for more serious influenza outcomes. Besides, our data also showed regional differences in the oseltamivir utilization and influenza complication rate. In fact, the oseltamivir utilization rate was higher in northern Taiwan than southern Taiwan, and the complication rate was highest in eastern Taiwan. There are many factors that can influence the regional variations in terms of oseltamivir utilization rates and influenza complication rates. For example, influenza virus activity and number of infected cases, demographics and clinical risk profiles of the population, time to access to the healthcare system, physician attitude on anti-influenza prescription, and the quality of outpatient and inpatient care, may all play a role. From these data, it is difficult to make any conclusion about the potential relation between oseltamivir use and influenza outcomes. However, the observed excess variability may suggest a disparity in terms of resource allocation among different regions in Taiwan. Public health efforts to overcome social factors to provide early anti-influenza drugs access may decrease influenza-related mortality [9]. Further study investigating optimal public anti-influenza drugs delivery and use, and research identifying area of inefficiency to correct potential under- or over-utilization is urgently needed to create strategies to prepare for the coming influenza pandemics.

There were several limitations in our study. First, the database did not include self-administered oseltamivir use. As there was a supply shortage of oseltamivir during the 2009 H1N1 pandemic, oseltamivir prescription data in the NHI database could represent the use of anti-influenza drugs throughout the entire country. Second, because the accuracy of influenza infection based on ICD-9-CM diagnostic codes was low, we only examined the infection outcomes among those who received oseltamivir treatment. Third, due to a lack of related information, we only examined the relation between crude oseltamivir utilization rate and crude influenza-related mortality without taking into account age distribution.
Conclusion
In conclusion, our study found that oseltamivir was widely used during the 2009 H1N1 pandemic in Taiwan, particularly those aged 7–18 years. Further study is needed to examine whether there is an over- or under-use of anti-influenza drugs in different age groups or regions and to examine the current policy of public use of anti-influenza drugs reduce influenza-associated morbidity and mortality.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
The study was jointly designed by all authors. CHL and CPS were responsible for the data analyses. MSL was the PI of the cohort study and main responsible for data acquisition. CHL, JLW and CHC wrote the first draft. CPS and JHC contributed to subsequent drafts of the paper. All authors contributed to approving the final manuscript.

Acknowledgement
No conflict of interest, financial or other, exists. The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of Taiwan CDC or the institutions with which the authors are affiliated.

Author details
1Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. “Department of Family Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei, Taiwan. “Department of Internal Medicine, E-Da Hospital/ I-Shou University, Kaohsiung, Taiwan. “Taiwan Centers for Disease Control, Taipei, Taiwan. “Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Received: 16 January 2013 Accepted: 5 July 2013

Published: 12 July 2013

References
1. World Health organization. Pandemic (H1N1) 2009 - update 122 Weekly update ; 2010. Available at: http://www.who.int/csr/don/2010_08_06/en/index.html. (Accessed Dec 11 2012).
2. European Centre for Disease Prevention and Control: Guide to public health measures to reduce the impact of influenza pandemics in Europe: “The ECDC Menu”. Available at: http://www.ecdc.europa.eu/ (Accessed Dec 11, 2012).
3. World Health organization: WHO guidelines for pharmacological management of pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/(Accessed Dec 11, 2012).
4. Fiore AE, Fry A, Shay D, Gubareva L, Breese JS, Uyeki TM; Centers for Disease Control and Prevention (CDC): antiviral agents for the treatment and chemoprophylaxis of influenza -- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommen Rep 2011, 60:1–24.
5. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneqhan CJ, Hama R, Thompson MJ: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012, 1, CD008965.
6. Doshi P: Neuraminidase inhibitors—the story behind the Cochrane review. BMJ 2009, 339:b5164.
7. Greene SK, Shay DK, Yin R, McCarthy NL, Baxter R, Jackson ML, Jacobsen SJ, Nordin JD, Irving SA, Naleway AL, Glanz JM, Lieu TA: Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, vaccine safety data link project, 2000–2010. Influenza Other Respi Viruses. 2012, 6:143–51.
8. Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, Chang FY, Chiu WT: Nationwide surveillance of influenza during the pandemic (2009–10) and post-pandemic (2010–11) periods in Taiwan. PlosC One 2012, 7:e36120.
9. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362:1708–1719.
10. Stocks AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisendorf E, St George K, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM: US antiviral resistance surveillance working group: oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–11. Emerg Infect Dis. 2012, 18:308–311.
11. Yang JR, Huang YP, Lin YC, Su CH, Kuo CY, Hsu LC, Wu HS, Liu MT. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Antivir Res. 2010, 80:256–262.
12. Lackenby A, Moran Glad J, Pedoby R, Miah S, Calatayud L, Bolotin S, Vipond L, Muir P, Guiver M, McMenamin J, Reynolds A, Moore C, Gunson R, Thompson C, Galiano M, Bermingham A, Ellis J, Zambon M. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011, 16:19784.
13. Chen CJ, Lee PI, Chang SC, Huang YC, Chiu HC, Hsieh YC, Chang SC, Chang FY, Ji SJ, Su SC, Shen GH, Chuang YC, Chen YS, Liu JW, Lin TY: Seroprevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan. PLoS One 2011, 6:e24440.
14. Karageorgopoulos DE, Vouloumanou EK, Korbila IP, Kapaskelis A, Falagas ME. Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza. PLoS ONE 2011, 6:e16990.
15. Doshi S, Kamimoto L, Finelli L, Perez A, Reingold A, Gershman K, Yousey-Hindes K, Arnold K, Ryan P, Lynfield R, Morin C, Baumbauch J, Hancock EB, Bennett NN, Zansky S, Thomas A, Schaffner W, Fry AM: Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005–2009. J Infect Dis 2011, 204:1848–1856.
16. Gao F, Loring C, Laviolette M, Bolton D, Daly ER, Bean C: Detection of 2009 pandemic influenza A(H1N1) virus infection in different age groups by using rapid influenza diagnostic tests. Influenza Other Respi Viruses 2012, 6:e30–34.
17. Van Kerkhove MD, Vandemeule AA, Shinde V, Jaramillo-Gutiérez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguchi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Hervaud JM, Orelle A, Palacios Y, Han D, van der Sande MA, Weidler HC, Tani K, Catter J, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Unghchak K, Pedoby R, Jain S, Mounts AW, WHO Working Group for Risk Factors for Severe H1N1pdm Infection: Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. Plos Med 2011, 8:e1001033.
18. Burch J, Coibett M, Stock C, Nicholson K, Elliot AJ, Duffy S, Westwood M, Palmer S, Stewart L: Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:537–545.
19. Hernandez JM, Lopez-Rodas V, Costas E: Antiviral agents: to treat or not to treat? An old dilemma revisited in light of new data from the 2009 influenza A(H1N1) pandemic. J Clin Virol 2010, 49:145–146.
20. Uyeki TM, Ejiama M, Anraku A, Shimabukuro K, Obuchi M, Kishida N, Hong X, Takashita E, Fujisaki S, Yamashita K, Horikawa H, Kato Y, Oguchi A, Fujita N, Tashiro M, Odaigiri T, Influenza Virus Surveillance Group of Japan: Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009–2010. Emerg Infect Dis 2011, 17:470–479.
21. Norwegian Institute of Public Health: Norwegian Prescription Database (NorPD) at the Norwegian Institute of Public Health. Available at: http://www.nordp.d/ (Accessed Dec 11, 2012).
22. Atkins CY, Patel A, Taylor TH Jr, Biggerstaff M, Merlin TI, Dulin SM, Erickson BA, Borse RH, Huneker K, Meltzer MI: Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis 2011, 17:1591–1598.
23. Mytton OT, Rutter PD, Donaldson LS: Influenza A(H1N1)pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year. Euro Surveill 2012, 17:20139.
24. National Institute for Health Data and Disease Control. Medicine sales in Denmark. Copenhagen,Denmark: Statens Serums Institut. Available at: http://www.medstat.dk/en. (Accessed Dec 11, 2012).
25. The European Centre for Disease Prevention and Control (ECDC): Daily Update 2009 influenza A(H1N1) pandemic, 28 December 2009, 14:00 CEST (Reported number of cumulative confirmed fatal 2009 pandemic influenza A (H1N1) cases in EU and EFTA countries, as 28 December 2009, 14:00 CEST, and in the rest of the world by country, as of 31 December 2009, 14:00 CEST, 2009.

26. Centers for Disease Control and Prevention (CDC): Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009, 58:1071–1074.

doi:10.1186/1471-2458-13-646
Cite this article as: Liu et al: Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan. BMC Public Health 2013 13:646.